Nang Competitors

Stocks . Taiwan . 
Stock . Nang Kuang Pharmaceutical
1752 Stock   36.40  0.55  1.49%   
Nang Kuang Pharmaceutical competes with Maxigen Biotech, Icares Medicus, Bionime Corp, Syngen Biotech, and Orient Europharma; as well as few others. Analyzing Nang Kuang competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Nang Kuang to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Nang Kuang vs SYN Tech Correlation

Very poor diversification

The correlation between Nang Kuang Pharmaceutical and 1777 is 0.88 (i.e., Very poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Nang Kuang Pharmaceutical and 1777 in the same portfolio, assuming nothing else is changed.

Moving together with Nang Stock

  0.632317 Hon Hai PrecisionPairCorr

Moving against Nang Stock

  0.852882 Cathay Financial HoldingPairCorr
  0.811303 Nan Ya PlasticsPairCorr
  0.792330 Taiwan SemiconductorPairCorr
  0.782303 United MicroelectronicsPairCorr
  0.780050 YuantaP shares TaiwanPairCorr

Nang Kuang Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Nang Kuang and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Nang and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Nang Kuang Pharmaceutical does not affect the price movement of the other competitor.

High positive correlations

1777
+ 0.84
1295
1295
+ 0.82
4737
8279
+ 0.81
6612
1777
+ 0.81
4737
4120
+ 0.77
1295
1295
+ 0.74
6612
  

High negative correlations

4737
- 0.69
1783
1777
- 0.67
1783
6748
- 0.58
4120
6748
- 0.56
8279
6748
- 0.54
6612
1295
- 0.53
1783

Risk-Adjusted Indicators

There is a big difference between Nang Stock performing well and Nang Kuang Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Nang Kuang's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Nang Kuang Competitive Analysis

The better you understand Nang Kuang competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Nang Kuang's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Nang Kuang's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
1752 1783 6612 4737 1295 8279 4120 6748 6657 1777
 1.49 
 36.40 
Nang
 1.07 
 46.20 
Maxigen
 0.97 
 81.80 
Icares
 6.87 
 51.50 
Bionime
 2.16 
 81.60 
Synbio
 1.51 
 134.50 
Syngen
 0.56 
 45.10 
Orient
 0.66 
 60.00 
ACRO
 8.42 
 51.10 
Energenesis
 0.41 
 72.00 
SYN
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Weakest
Fair
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Mild
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Unknown
Low
Low
Low
Unknown
Low
High
Unknown
Unknown
Low
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Hold
Sell
Strong Sell
Cautious Hold
Strong Sell
Sell
Cautious Hold
Strong Sell
Strong Sell
Current Ratio
N/A
7.81
5.31
1.18
N/A
1.89
N/A
N/A
N/A
1.55
Net Asset
N/A
1.27 B
965.87 M
4.56 B
N/A
N/A
9.4 B
N/A
N/A
2.71 B
Profit Margin
N/A
0.19
0.27
0.0454
N/A
14.8
-0.0197
N/A
N/A
0.33
EBITDA
N/A
130.56 M
102.71 M
248.29 M
N/A
275.24 M
313.89 M
N/A
N/A
192.76 M
Operating Margin
N/A
0.16
0.28
0.0548
N/A
17.76
-0.0086
N/A
N/A
0.21
Current Valuation
N/A
3.32 B
2.39 B
6.7 B
N/A
3.58 B
5.9 B
N/A
N/A
3.16 B
Price To Book
N/A
3.24
3.25
2.31
N/A
3.79
1.07
N/A
N/A
1.75
Retained Earnings
N/A
(14 M)
N/A
180 M
N/A
N/A
N/A
N/A
N/A
N/A
Current Asset
N/A
623 M
N/A
1.39 B
N/A
N/A
N/A
N/A
N/A
N/A
Five Year Return
N/A
N/A
N/A
3.98
N/A
N/A
N/A
N/A
N/A
3.36
Beta
N/A
1.05
0.82
0.68
N/A
1.02
0.4
N/A
N/A
0.17
Number Of Employees
N/A
20
14
21
N/A
9
21
N/A
N/A
178
Shares Outstanding
N/A
84.7 M
34.16 M
60.62 M
N/A
23.1 M
86.75 M
N/A
N/A
44.59 M
Cash Flow From Operations
N/A
117.59 M
38.57 M
269.72 M
N/A
171.18 M
77.65 M
N/A
N/A
120.43 M
Annual Yield
N/A
0.0167
0.0038
0.0255
N/A
N/A
0.0235
N/A
N/A
0.0225
Total Debt
N/A
16.62 M
2.8 M
1.16 B
N/A
251.18 M
1.68 B
N/A
N/A
549.52 M
Return On Equity
N/A
0.0926
0.13
0.0467
N/A
21.75
-0.0268
N/A
N/A
0.14
Z Score
N/A
N/A
N/A
2.4
N/A
8.4
0.6
N/A
N/A
3.6
Return On Asset
N/A
0.0454
0.0835
0.0151
N/A
10.11
-0.0027
N/A
N/A
0.0391
Book Value Per Share
N/A
14.75
25.38
33.68
N/A
39.33
33.54
N/A
N/A
48.66
Current Liabilities
N/A
63 M
N/A
935 M
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
N/A
1.27 B
965.87 M
4.56 B
N/A
N/A
9.4 B
N/A
N/A
2.71 B
Debt To Equity
N/A
1.5
0.03
100.7
N/A
27.6
N/A
N/A
N/A
51.2
Last Dividend Paid
N/A
N/A
0.5
2.0
N/A
2.5
0.85
N/A
N/A
1.93
Target Price
N/A
N/A
N/A
121.0
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
N/A
2.28
0.28
2.9
N/A
N/A
0.45
N/A
N/A
N/A
Market Capitalization
N/A
5.02 B
4.36 B
4.71 B
N/A
3.54 B
3.13 B
N/A
N/A
3.83 B
Price To Earning
N/A
33.55
59.67
23.69
N/A
18.78
N/A
N/A
N/A
16.06
Price To Sales
N/A
6.63
5.75
2.24
N/A
2.85
0.68
N/A
N/A
5.14
Net Income
N/A
87.67 M
58.6 M
87.41 M
N/A
183.85 M
120.17 M
N/A
N/A
103.83 M
Earnings Per Share
N/A
1.23
3.88
1.56
N/A
7.93
0.54
N/A
N/A
5.68
Shares Owned By Insiders
N/A
51.89
54.23
47.14
N/A
N/A
65.1
N/A
N/A
59.32
Revenue
N/A
511.98 M
393.92 M
1.85 B
N/A
1.24 B
4.77 B
N/A
N/A
746.6 M
Working Capital
N/A
560 M
N/A
450 M
N/A
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
N/A
390.34 M
301 M
388.32 M
N/A
110.77 M
N/A
N/A
N/A
668.13 M
Cash Per Share
N/A
5.62
8.86
6.76
N/A
4.8
N/A
N/A
N/A
22.25
Gross Profit
N/A
261.03 M
322.88 M
783.13 M
N/A
377.38 M
2.15 B
N/A
N/A
242.35 M
Day Typical Price
36.45
46.18
81.8
52.5
82.2
134.0
44.92
60.03
52.37
72.2
Accumulation Distribution
0.0123
0.0161
0.0097
0.055
0.0404
0.0258
0.0144
0.0311
0.0901
0.011
Market Facilitation Index
0.45
0.75
0.8
3.0
3.4
3.5
0.65
1.9
5.0
0.8
Daily Balance Of Power
(1.22)
(0.67)
(1.00)
(1.27)
(0.53)
0.5714
0.3846
(0.21)
(0.94)
(0.38)
Period Momentum Indicator
(0.55)
(0.50)
(0.80)
(3.80)
(1.80)
2.0
0.25
(0.40)
(4.70)
(0.30)
Rate Of Daily Change
0.99
0.99
0.99
0.93
0.98
1.02
1.01
0.99
0.92
1.0
Day Median Price
36.48
46.18
81.8
53.0
82.5
133.75
44.83
60.05
53.0
72.3
Price Action Indicator
(0.35)
(0.22)
(0.40)
(3.40)
(1.80)
1.75
0.4
(0.25)
(4.25)
(0.45)
Relative Strength Index
37.49
58.65
50.21
34.47
34.53
61.73
51.3
N/A
58.13
36.02
Coefficient Of Variation
(512.74)
1083.04
(1,430)
(557.96)
(395.88)
(10,627)
(1,742)
(737.49)
1607.86
(658.47)
Mean Deviation
0.3823
0.9625
1.24
1.21
1.28
1.11
0.7526
1.4
2.11
0.4593
Jensen Alpha
(0.12)
0.1039
(0.16)
(0.30)
(0.42)
(0.03)
(0.07)
(0.29)
0.2123
(0.1)
Total Risk Alpha
(0.14)
0.0505
(0.26)
(0.39)
(0.50)
(0.10)
(0.12)
(0.37)
0.0339
(0.13)
Sortino Ratio
N/A
0.0619
N/A
N/A
N/A
N/A
N/A
N/A
0.0514
N/A
Downside Variance
N/A
1.75
N/A
N/A
N/A
N/A
N/A
N/A
8.71
N/A
Standard Deviation
0.5287
1.37
2.1
1.66
1.63
1.61
1.03
1.98
3.16
0.6057
Kurtosis
1.17
3.62
9.24
3.1
0.5789
3.57
1.3
1.43
2.77
0.3996
Potential Upside
1.06
1.78
3.7
2.27
2.44
2.38
1.47
3.23
5.35
0.8299
Treynor Ratio
(0.83)
0.3147
(1.60)
2.46
7.32
(0.20)
27.56
(1.21)
(0.25)
0.946
Maximum Drawdown
2.15
8.45
13.91
7.86
8.13
8.76
5.44
10.5
17.79
2.96
Variance
0.2795
1.89
4.41
2.77
2.64
2.6
1.05
3.91
9.99
0.3668
Market Risk Adjusted Performance
(0.82)
0.3247
(1.59)
2.47
7.33
(0.19)
27.57
(1.20)
(0.24)
0.956
Risk Adjusted Performance
(0.14)
0.0715
(0.04)
(0.12)
(0.18)
(0)
(0.04)
(0.09)
0.0527
(0.11)
Skewness
0.505
0.4161
2.39
(1.02)
0.3204
0.6889
(0.71)
0.3782
0.5675
(0.23)
Semi Deviation
N/A
1.11
N/A
N/A
N/A
N/A
N/A
N/A
2.54
N/A
Information Ratio
(0.28)
0.0596
(0.09)
(0.21)
(0.28)
(0.04)
(0.10)
(0.16)
0.048
(0.23)
Value At Risk
(0.93)
(1.59)
(2.67)
(2.64)
(2.54)
(2.31)
(1.81)
(2.49)
(4.12)
(1.09)
Expected Short fall
N/A
(1.06)
N/A
N/A
N/A
N/A
N/A
N/A
(2.51)
N/A
Downside Deviation
N/A
1.32
N/A
N/A
N/A
N/A
N/A
N/A
2.95
N/A
Semi Variance
N/A
1.23
N/A
N/A
N/A
N/A
N/A
N/A
6.45
N/A

Nang Kuang Competition Performance Charts

Five steps to successful analysis of Nang Kuang Competition

Nang Kuang's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Nang Kuang Pharmaceutical in relation to its competition. Nang Kuang's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Nang Kuang in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Nang Kuang's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Nang Kuang Pharmaceutical, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Nang Kuang position

In addition to having Nang Kuang in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Junk Bonds Funds Thematic Idea Now

Junk Bonds Funds
Junk Bonds Funds Theme
Funds or Etfs that invest most of their assets into speculative (junk) bonds or to other fixed income instruments with interest rates 3 to 4 percentage points above government issues. The Junk Bonds Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Junk Bonds Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Nang Stock Analysis

When running Nang Kuang's price analysis, check to measure Nang Kuang's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nang Kuang is operating at the current time. Most of Nang Kuang's value examination focuses on studying past and present price action to predict the probability of Nang Kuang's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nang Kuang's price. Additionally, you may evaluate how the addition of Nang Kuang to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY